Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 14/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.53 |
| ▸ | CDK9 | P50750 | 9/20 | 0.53 |
| ▸ | MTOR | P42345 | 6/20 | 0.49 |
| ▸ | SMG1 | Q96Q15 | 5/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 10/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.47 |
| ▸ | CDK7 | P50613 | 5/20 | 0.47 |
| ▸ | CCNH | P51946 | 5/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2538339 | 0.91 | CCNT1 (0.49) | CDK1CCNT1CCNB1CDK9CDK2 | |
| SCHEMBL2540573 | 0.90 | CDK1 (0.56) | CDK1CCNT1CCNB1CDK9MTOR | |
| SCHEMBL2544646 | 0.86 | IKBKB (0.48) | — | |
| SCHEMBL2542192 | 0.86 | PLK1 (0.48) | CDK1CCNT1CCNB1CDK9CDK2 | |
| SCHEMBL2541106 | 0.84 | CDK1 (0.57) | CDK1CCNT1CCNB1CDK9MTOR | |
| SCHEMBL15086017 | 0.84 | CCNT1 (0.43) | CDK1CCNT1CCNB1CDK9CDK2 | |
| SCHEMBL2545759 | 0.83 | CDK1 (0.55) | CDK1CCNT1CCNB1CDK9MTOR | |
| SCHEMBL2541901 | 0.81 | PLK1 (0.43) | CDK1CCNT1CCNB1CDK9CDK2 | |
| SCHEMBL2546325 | 0.80 | CAMK2D (0.53) | CDK1CCNB1SMG1CDK2CDK7 | |
| SCHEMBL2546287 | 0.80 | CAMK2D (0.53) | CDK1CCNT1CCNB1CDK9CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | claimed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | claimed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | claimed |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | disclosed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | MAP3K20, MAP3K1, MAP3K2 | CDK1 129/4885CCNT1 1213/4885CCNB1 1308/4885 |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | NFKBIA, IRAK1, IRAK3 | CDK1 465/4885CCNT1 3334/4885CCNB1 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.